Bli medlem
Bli medlem

Du är här

2016-10-18

PExA: PExA receives Horizon 2020 funding

The European Commission has selected PExAs project "BREATH: Biomarkers
for Respiratory diseases detected in Exhaled Air through a new
Technological instrument for research and Healthcare markets" for
funding through the Research and Innovation Framework Program Horizon
2020.

The European Commission has selected PExAs projects for funding of a
Phase 1 feasibility study through the "SME (Small Medium Enterprises)
Instrument" call within EU's Research and Innovation Framework
Program Horizon 2020. Each project receives 50.000 Euro to carry out
a feasibility study and to prepare a Phase 2 program which, if
granted, could result in significant additional funding. A Phase 2
program, could be financed up to EUR 2.5 million by the European
Commission.

The goal of the feasibility study is to define and optimize the
technical strategy, focusing on new proprietary disposable products
and new service functions that will facilitate the use of the
instrument. An additional objective is to define a five-year plan for
the second phase of commercialization, targeting hospitals and health
care institutions.

The feasibility study is expected to be completed during the first
half of 2017.

CEO Erik Ekbo comments
- We are very pleased to have been selected in competition with many
other qualified companies and that the European Commission has
decided to support this project financially. The focus is now on
reaching the targets set for Phase 1 and to prepare for the Phase 2
program.

For further information, please contact:
Erik Ekbo, CEO
Phone: +46 723-92 30 30
E-mail: erik@pexa.se

This information is information which PExA AB is obligated to publish
under the EU Market Abuse Regulation. The information was provided
through the agency of above contact person, for publication on
October 18, 2016.

PExA AB (556956-9246) develops and markets a research instrument with
associated products and services to pulmonary researchers for easy
and non-invasive sampling, in order to study respiratory diseases
such as asthma and chronic obstructive pulmonary disease, COPD.
Sampling with PExA can be used to detect lung diseases at an early
stage. The sample can be compared to a "blood test for the small
airways ". The aim is to facilitate the development of reliable and
more individualized diagnosis, monitoring and treatment of
respiratory diseases. The original idea and research behind the
method comes from the unit for Occupational and Environmental
Medicine at the Sahlgrenska Academy at Gothenburg University.
Commercial operations started in 2010 with the support of GU Ventures
incubator, and the company is founded by inventor, key employees,
business angels and GU Ventures. The company's B-shares are listed on
AktieTorget.

-----------------------------------------------------------
http://news.cision.com/pexa/r/pexa-receives-horizon-2020-funding,c2103347
http://mb.cision.com/Main/12904/2103347/576423.pdf

Författare ATORG

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.